Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities

Slambrouck, Charles Van; Huh, Jooryung; Suh, Cheolwon; Song, Joo Y.; Menon, Madhu P.; Sohani, Aliyah R.; Duffield, Amy S.; Goldberg, Reva C.; Dama, Paola; Kiyotani, Kazuma; Godfrey, James; Fitzpatrick, Carrie; Kline, Justin; Smith, Sonali M.; Jaffe, Elaine S.; Hartmann, Sven; Venkataraman, Girish

doi:10.1038/s41379-019-0428-0

Cited by 17 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The robust expression of B-cell transcription factors PAX5, OCT2 and BOB1 in the majority of NLPHL aids in the separation from CHL [ 35 , 36 , 37 ] ( Figure 2 D–F). Additionally, MEF2B positivity and a lack of nuclear STAT6 have been shown to distinguish NLPHL from CHL [ 38 , 39 ].…”

Section: Histologic and Immunophenotypic Diagnosis Of Nlphlmentioning

confidence: 99%

“…MEF2B is positive in LP cells of NLPHL and negative in CHL [ 38 ]. STAT6 shows a nuclear positivity in CHL, whereas a nuclear positivity is absent in LP cells, although weak cytoplasmic staining can be detected in up to 74% of cases [ 39 ]. Although less commonly employed in a clinical setting, FISH for BCL6 is positive in NLPHL but not in CHL [ 44 , 53 ].…”

Section: Diagnostic Mimics and Overlapsmentioning

confidence: 99%

See 1 more Smart Citation

Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics

Younes

Rojansky

Menke

et al. 2021

Cancers

View full text Add to dashboard Cite

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) represents approximately 5% of Hodgkin lymphoma and typically affects children and young adults. Although the overall prognosis is favorable, variant growth patterns in NLPHL correlate with disease recurrence and progression to T-cell/histiocyte-rich large B-cell lymphoma or frank diffuse large B-cell lymphoma (DLBCL). The diagnostic boundary between NLPHL and DLBCL can be difficult to discern, especially in the presence of variant histologies. Both diagnoses are established using morphology and immunophenotype and share similarities, including the infrequent large tumor B-cells and the lymphocyte and histiocyte-rich microenvironment. NLPHL also shows overlap with other lymphomas, particularly, classic Hodgkin lymphoma and T-cell lymphomas. Similarly, there is overlap with non-neoplastic conditions, such as the progressive transformation of germinal centers. Given the significant clinical differences among these entities, it is imperative that NLPHL and its variants are carefully separated from other lymphomas and their mimics. In this article, the characteristic features of NLPHL and its diagnostic boundaries and pitfalls are discussed. The current understanding of genetic features and immune microenvironment will be addressed, such that a framework to better understand biological behavior and customize patient care is provided.

show abstract

Section: Histologic and Immunophenotypic Diagnosis Of Nlphlmentioning

confidence: 99%

Section: Diagnostic Mimics and Overlapsmentioning

confidence: 99%

Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics

Younes

Rojansky

Menke

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…29 The results of immunohistochemical studies were consistent with these genetic alterations. van Slambrouck et al 23 reported that 80% of CHLs expressed STAT6 on HRS cells, and Skinnider et al 24 found that 78% expressed pSTAT6. In our study, either STAT6 or pSTAT6 expression was present in 70% of CHLs, which is comparable with previous reports.…”

Section: Discussionmentioning

confidence: 99%

“…The threshold used here is comparable to that from a prior publication involving the same clone antibody. 15,23,25,26 For other antigens, tissue samples were considered positive if > 20% of the tumor cells were positive.…”

Section: Histologic and Immunohistochemical Stainingmentioning

confidence: 99%

“…18 Along with the frequent activation of the JAK/STAT pathway, HRS cells in CHLs are highly associated with the expression of STAT6, pSTAT6, and pSTAT3, with 80%, 78%, and 87% positivity, respectively. 23,24 In this study, we performed immunohistochemistry for STAT6, pSTAT6, and pSTAT3 on CHLs and nodal PTCLs with HRS-like cells and assessed the diagnostic utility of these immunohistochemical markers in distinguishing HRS cells from HRS-like cells. In addition, we also performed PD-L1 immunohistochemistry to reconfirm its utility in differentiating the 2.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg–like Cells

Satou

Takahara

Yamashita

et al. 2023

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Peripheral T-cell lymphomas (PTCLs), particularly nodal lymphomas of T-follicular helper cell origin, may include Hodgkin/Reed-Sternberg (HRS)-like cells in their microenvironment. These HRS-like cells are morphologically indistinguishable from HRS cells of classic Hodgkin lymphoma (CHL). Therefore, PTCLs with HRS-like cells pose a differential diagnosis vis-à-vis CHL. A previous study reported that, in contrast to HRS cells, programmed death-ligand 1 (PD-L1) expression is rare in HRS-like cells of PTCLs and suggested that PD-L1 immunohistochemistry is useful to differentiate HRS cells and HRS-like cells. In this study, we analyzed 21 patients with PTCL with HRS-like cells and 34 patients with CHL and assessed the diagnostic utility of STAT6, pSTAT6, and pSTAT3 immunohistochemistry in distinguishing HRS cells from HRS-like cells. In addition, we also performed PD-L1 immunohistochemistry to reconfirm its utility in distinguishing the 2 diseases. Compared with HRS cells in CHLs, HRS-like cells in PTCLs showed significantly less positivity for STAT6 (9.6% vs. 70%, P<0.001), pSTAT6 (9.6% vs. 70%, P<0.001), and PD-L1 (9.6% vs. 85%, P<0.001). Thus, we reconfirmed the diagnostic utility of PD-L1 immunohistochemistry in distinguishing CHLs from PTCLs with HRS-like cells. In contrast, both HRS-like and HRS cells were highly associated with pSTAT3 expression, with no significant difference in positive cell frequency (86% vs. 91%, P=0.66). On the basis of these findings, we conclude that, in addition to PD-L1, STAT6 and pSTAT6 immunohistochemistry are helpful diagnostic tools to distinguish CHLs from PTCLs with HRS-like cells.

show abstract

Markers and Immunoprofile of Lymphoid Neoplasms

Tuffaha,

Guski,

Kristiansen

2023

Immunohistochemistry in Tumor Diagnostics

View full text Add to dashboard Cite

Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities

Cited by 17 publications

References 35 publications

Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics

Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics

Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg–like Cells

Markers and Immunoprofile of Lymphoid Neoplasms

Contact Info

Product

Resources

About